# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Central Nervous System Lymphoma, Primary

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 201 results.
Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Status: Unknown status
Last Changed: Jun 22, 2016
First Received: May 20, 2016
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): pembrolizumab
Locations: Dept of Internal Medicine, Vienna, Austria
Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma
Status: Unknown status
Last Changed: Dec 06, 2016
First Received: Dec 06, 2016
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): ketogenic diet, Routine diet
Locations: Beijing Tiantan Hospital, Beijing, Beijing, China
a Phase II Study in Primary Central Nervous System Lymphoma
Status: Unknown status
Last Changed: Apr 04, 2007
First Received: Apr 03, 2007
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): Methotrexate, Methylprednisolone, Temozolomide
Locations: Changhua Christian Hospital, Changhua, Taiwan
China Medical University Hospital, Taichung, Taiwan
National Cheng Kung University Hospital, TaiNan, Taiwan
Mackay Memorial Hospital, Taipei, Taiwan
MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma
Status: Unknown status
Last Changed: Apr 13, 2015
First Received: Mar 26, 2015
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): R-MT followed by auto-HSCT
Locations: Lijuan Deng, Beijing, Beijing, China
Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Status: Recruiting
Last Changed: Feb 12, 2020
First Received: Aug 28, 2019
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): Camrelizumab
Locations: Sanbo Brain Hospital Capital Medical University, Beijing, China
Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma
Status: Recruiting
Last Changed: Sep 10, 2019
First Received: Sep 10, 2019
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): rituximab in combination with methotrexate, cytarabine and dexamethasone
Locations: Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Status: Withdrawn
Last Changed: Nov 16, 2018
First Received: Apr 19, 2017
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): PQR309
Locations: Aix-Marseilles Université, Marseille, France
Service de Neurology CHRU de Nancy, Nancy, France
Hôpital Pitié-Sâlpétrier,, Paris, France
Hématologie, Départment d'ongolgie médicale, Saint-Herblain, France
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
Status: Not yet recruiting
Last Changed: Jul 08, 2020
First Received: Jul 08, 2020
Disease(s): Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Intervention(s): Durvalumab, Acalabrutinib
Locations: Washington University School of Medicine, Saint Louis, Missouri, United States
PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Status: Completed
Last Changed: Jul 09, 2019
First Received: Feb 01, 2016
Disease(s): Primary Central Nervous System Lymphoma
Intervention(s): PQR309
A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)
Status: Not yet recruiting
Last Changed: Jul 07, 2020
First Received: Jul 07, 2020
Disease(s): Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Intervention(s): F520